Vistin Pharma ASALTS:0RAM 77 Return-on-Tangible-Equity is 25.32% as of Mar. 2026, which is 108% above its 10-year median of 12.18. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.61 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 897 Drug Manufacturers companies, Vistin Pharma ASA ranks better than 82.05% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Vistin Pharma ASA's annualized net income for the quarter that ended in Mar. 2026 was kr86.0 Mil. Vistin Pharma ASA's average shareholder tangible equity for the quarter that ended in Mar. 2026 was kr339.6 Mil. Therefore, Vistin Pharma ASA's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 25.32%.
The historical rank and industry rank for Vistin Pharma ASA's Return-on-Tangible-Equity or its related term are showing as below:
LTS:0RAM'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -31.4 Med: 12.18 Max: 45.9
Current: 23.05
During the past 13 years, Vistin Pharma ASA's highest Return-on-Tangible-Equity was 45.90%. The lowest was -31.40%. And the median was 12.18%.
LTS:0RAM's Return-on-Tangible-Equity is ranked better than 82.05% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs LTS:0RAM: 23.05
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Vistin Pharma ASA Return-on-Tangible-Equity Related Terms
Vistin Pharma ASA Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAM vs ZTS, UTHR, VTRS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 25.32% mean?
Vistin Pharma ASA (LTS:0RAM) has a Return-on-Tangible-Equity of 25.32% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vistin Pharma ASA and its competitors. This is 108% above median its historical median of 12.18. According to the industry distribution chart, Vistin Pharma ASA ranks #161 out of 897 companies in the Drug Manufacturers industry, placing it in the top 17.9%.
Is Vistin Pharma ASA's Return-on-Tangible-Equity too high?
Vistin Pharma ASA's current Return-on-Tangible-Equity of 25.32% is 108% above median its 10-year median of 12.18. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Vistin Pharma ASA's value of 25.32% is 220.5% above this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #161 out of 897 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #161 out of 897 companies for Return-on-Tangible-Equity. This places Vistin Pharma ASA in the top 18% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.90. Vistin Pharma ASA's value of 25.32% is 220.5% above this benchmark. While the company's 10-year median is 12.18 vs. the industry median of 7.90, Vistin Pharma ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current Return-on-Tangible-Equity of 25.32% is 220.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Return-on-Tangible-Equity is 25.32%, which is 108% above median its own 10-year median of 12.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.61, compared to a current price of kr20.70 — trading 19.2% below its estimated fair value. The current Return-on-Tangible-Equity is 25.32%, which is 108% above median its 10-year median of 12.18 and 220.5% above the Drug Manufacturers industry median of 7.90. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Return-on-Tangible-Equity is 25.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.70 is trading 19.2% below its estimated GF Value™ of kr25.61.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
Return-on-Tangible-Equity: 25.32% (108% above median its 10-year median of 12.18)
GF Value™: kr25.61 vs. price of kr20.70 (19.2% below fair value)
Industry Position: 220.5% above the Drug Manufacturers median (#161 of 897)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score
Get the complete analysis for LTS:0RAM
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
